OBJECTIVES: To estimate the budget impact analysis of replacing Tobramycin Inhalation Solution (TIS) by TIP in the public health care system. METHODS: A financial cash flow of treatment, concomitant treatment (ciprofloxacin) was estimated using TIP instead of TIS in the 315 patients currently identified receiving treatment. Efficacy is the same between the two presentations (Konstan, 2011); adverse events do not represent additional costs. However the time needed to nebulization treatment, and device cleaning is longer with TIS: 28 and 33 minutes more per day, respectively. Therefore a societal impact is estimated using the societal time value for economic evaluations of US$2.64 hour. (ER 1US$=13MX$). RESULTS: The cycle cost per patient of TIS=US$2269.23 and TIP=US$2155.76. The annual 6-cycles cost is US$13,617.81 for TIS and US$12,937.21 for TIP. Savings account for US$680.52 per patient (5%). The Health System could be saving US$214,442.30. The difference in the hours invested to drug administration between TIS and TIP is 78.4 hours-year, and the difference for cleaning the device is 92.4 hours-year, less for TIP in both cases. Economically, it represents an incremental societal investment of using TIS of $1798 per patient a year. CONCLUSIONS: The time burden to receive treatment in CF is huge. Patients spend around 2 hours a day. TIP represents an opportunity for saving both health care resources, and valuable time to patients, and caregivers.